Market Overview:
Gastritis refers to the inflammation or irritation of the stomach lining. Common symptoms of gastritis include abdominal pain, bloating, nausea and vomiting. Gastritis is often caused by infection with Helicobacter pylori bacteria, excessive alcohol consumption, smoking, stress and certain medications. Treatment for gastritis mainly focuses on minimizing symptoms, protecting the stomach lining and eradicating the underlying cause. Key treatment options include antacids, H2 blockers, proton pump inhibitors and antibiotics.

The Gastritis Treatment Market is estimated to be valued at US$ 131.76 Bn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Rising incidence of gastric ulcers is a major factor driving the growth of gastritis treatment market. Gastric ulcers refer to open sores or lesions that develop on the inner lining of the stomach. Changes in lifestyle and eating habits have significantly increased the cases of gastric ulcers globally. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 4 million Americans suffer from acute gastric ulcers each year. Growing geriatric population is also contributing to the high prevalence of gastritis as age is a primary risk factor for gastric disorders. Furthermore, increasing consumption of non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief has emerged as one of the leading causes of gastritis, thus supporting market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The threat of new entrants is low as gastritis treatment market requires high R&D investments and established distribution networks.

Bargaining power of buyers: The bargaining power of buyers is high due to availability of generic drugs and treatment alternatives.

Bargaining power of suppliers: Suppliers have moderate bargaining power due to presence of many suppliers and accessibility to raw materials.

Threat of new substitutes: Threat of substitutes is moderate as alternative treatment options are available.

Competitive rivalry: High due to presence of many global and local players.

SWOT Analysis

Strength: Wide range of treatment options available and increasing healthcare expenditure. Easy accessibility and availability of OTC drugs.

Weakness: Presence of alternative gastroprotective agents and recurrence of the disease affecting treatment compliance. Side effects associated with few drugs.

Opportunity: Growth in emerging markets, rising geriatric population susceptible to gastritis. New product launches focusing on disease-specific treatments.

Threats: Patent cliffs of major drugs, pricing pressure from regulatory bodies and increasing popularity of herbal remedies.

Key Takeaways

The global gastritis treatment market is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing consumption of alcohol, smoking, and stress levels among individuals. The market size for 2023 is US$ 131.76 Bn.

Regionally, North America dominated the market with over 30% share in 2023 due to higher adoption of advanced treatment options and growing healthcare expenditure. Asia Pacific is anticipated to register fastest CAGR during the forecast period driven by rising awareness and increasing discretionary spending on healthcare in developing countries.

Key players operating in the gastritis treatment market are Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited. Pfizer dominates the market with its wide product portfolio of proton pump inhibitors indicated for treatment of various gastric disorders.